Michael Kurin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael Kurin has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Katarina Greer
Division of Gastroenterology, Louis Stokes VA Medical Center and Case Western Reserve University, Cleveland, Ohio
2 shared publications- Ronnie Fass
Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH
2 shared publications Abbinaya Elangovan
Internal Medicine‐Pediatrics Residency Program MetroHealth Medical Center Cleveland Ohio USA
1 shared publicationAchintya D. Singh
Department of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, USA
1 shared publicationBasmah Al Dulaijan
Internal Medicine Residency Program Department of General Internal Medicine University Hospitals Cleveland Medical Center Cleveland Ohio USA
1 shared publicationDariush Shahsavari
Gastroenterology Section, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
1 shared publication
Latest Publications
- 5 July 2025
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 21 (11) , 1181-1187
Prevalence of dysphagia after Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a national propensity score study
- 5 July 2025
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 21 (11) , 1181-1187
Prevalence of dysphagia after Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a national propensity score study
- 23 March 2024
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 69 (6) , 1913-1914
An Unusual Case of Refractory Esophagitis and Esophageal Diverticulum
- 23 March 2024
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 69 (6) , 1913-1914
An Unusual Case of Refractory Esophagitis and Esophageal Diverticulum
- Open Access
- 1 January 2024
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 11 (1) , e01149
Esophageal Cicatricial Pemphigoid
Cicatricial pemphigoid (CP) is a rare autoimmune blistering disorder, which affects the skin, eyes, and mucous membranes. The annual incidence of CP is 1/100,000. Esophageal involvement is rare and usually occurs in disseminated disease. Esophageal disease presents with dysphagia and weight loss and can be difficult to treat. We present a case of a 65-year-old woman with esophageal CP whose symptoms improved with esophageal dilatation and rituximab infusions.
- 1 January 2024
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 11 (1) , e01149
Open AccessEsophageal Cicatricial Pemphigoid
Cicatricial pemphigoid (CP) is a rare autoimmune blistering disorder, which affects the skin, eyes, and mucous membranes. The annual incidence of CP is 1/100,000. Esophageal involvement is rare and usually occurs in disseminated disease. Esophageal disease presents with dysphagia and weight loss and can be difficult to treat. We present a case of a 65-year-old woman with esophageal CP whose symptoms improved with esophageal dilatation and rituximab infusions.
- 29 June 2023
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 58 (4) , 342-348
The Impact of Chronic Cannabis Use on Esophageal Motility in Patients Referred for Esophageal Manometry
Background: Tetrahydrocannabinol, the main psychoactive compound in cannabis, binds with high affinity to the cannabinoid 1 receptor. Small randomized controlled studies using conventional manometry have shown that the cannabinoid 1 receptor can modulate esophageal function, namely transient lower esophageal sphincter relaxation frequency and lower esophageal sphincter tone. The effect of cannabinoids on esophageal motility in patients referred for esophageal manometry has not been fully elucidated using high-resolution esophageal manometry (HREM). We aimed to characterize the clinical effect of chronic cannabis use on esophageal motility utilizing HREM. Methods: Patients who underwent HREM from 2009 to 2019 were identified at 4 academic medical centers. The study group consisted of patients with a noted history of chronic cannabis use, a diagnosis of cannabis-related disorder, or a positive urine toxicology screen. Age and gender-matched patients with no history of cannabis use were selected to form the control group. Data on HREM metrics based on the Chicago classification V3, and the prevalence of esophageal motility disorders were compared. Confounding effects of BMI and medications on esophageal motility were adjusted for. Results: Chronic cannabis use was found to be an independent negative predictor of weak swallows (β=−8.02, P=0.0109), but not a predictor of failed swallows (P=0.6890). The prevalence of ineffective esophageal motility was significantly lower in chronic cannabis users compared with nonusers (OR=0.44, 95% CI 0.19–0.93, P=0.0384). There was no significant difference in the prevalence of other esophageal motility disorders between the 2 cohorts. In patients with dysphagia as their primary indication for HREM, chronic cannabis use was found to be independently associated with increased median integrated relaxation pressure (β=6.638, P=0.0153) and increased mean lower esophageal sphincter resting pressure (β=10.38, P=0.0084). Conclusions: Chronic cannabis use is associated with decreased weak swallows and reduced prevalence of ineffective esophageal motility in patients referred for esophageal manometry. In patients referred for dysphagia, chronic cannabis use is associated with increased integrated relaxation pressure and lower esophageal sphincter resting pressure, though not to levels above the normal range.
- 29 June 2023
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 58 (4) , 342-348
The Impact of Chronic Cannabis Use on Esophageal Motility in Patients Referred for Esophageal Manometry
Background: Tetrahydrocannabinol, the main psychoactive compound in cannabis, binds with high affinity to the cannabinoid 1 receptor. Small randomized controlled studies using conventional manometry have shown that the cannabinoid 1 receptor can modulate esophageal function, namely transient lower esophageal sphincter relaxation frequency and lower esophageal sphincter tone. The effect of cannabinoids on esophageal motility in patients referred for esophageal manometry has not been fully elucidated using high-resolution esophageal manometry (HREM). We aimed to characterize the clinical effect of chronic cannabis use on esophageal motility utilizing HREM. Methods: Patients who underwent HREM from 2009 to 2019 were identified at 4 academic medical centers. The study group consisted of patients with a noted history of chronic cannabis use, a diagnosis of cannabis-related disorder, or a positive urine toxicology screen. Age and gender-matched patients with no history of cannabis use were selected to form the control group. Data on HREM metrics based on the Chicago classification V3, and the prevalence of esophageal motility disorders were compared. Confounding effects of BMI and medications on esophageal motility were adjusted for. Results: Chronic cannabis use was found to be an independent negative predictor of weak swallows (β=−8.02, P=0.0109), but not a predictor of failed swallows (P=0.6890). The prevalence of ineffective esophageal motility was significantly lower in chronic cannabis users compared with nonusers (OR=0.44, 95% CI 0.19–0.93, P=0.0384). There was no significant difference in the prevalence of other esophageal motility disorders between the 2 cohorts. In patients with dysphagia as their primary indication for HREM, chronic cannabis use was found to be independently associated with increased median integrated relaxation pressure (β=6.638, P=0.0153) and increased mean lower esophageal sphincter resting pressure (β=10.38, P=0.0084). Conclusions: Chronic cannabis use is associated with decreased weak swallows and reduced prevalence of ineffective esophageal motility in patients referred for esophageal manometry. In patients referred for dysphagia, chronic cannabis use is associated with increased integrated relaxation pressure and lower esophageal sphincter resting pressure, though not to levels above the normal range.
- Open Access
- 30 May 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (6) , 917
Irritable Bowel Syndrome Is an Independent Risk Factor for Developing Opioid Use Disorder in Patients with Inflammatory Bowel Disease
Background: Symptoms of IBS can fluctuate even when IBD is in clinical remission. Patients with IBD are at an increased risk of developing opioid addiction. The aim of the study was to determine whether IBS is an independent risk factor for developing opioid addiction and related gastrointestinal symptoms in patients with IBD. Methods: We identified patients with Crohn’s disease (CD)+IBS and ulcerative colitis (UC) + IBS using TriNetX. The control groups consisted of patients with CD or UC alone without IBS. The main outcome was to compare the risks of receiving oral opioids and developing opioid addiction. A subgroup analysis was performed by selecting patients who were prescribed oral opioids and to compare with those not prescribed opioids. Gastrointestinal symptoms and mortality rates were compared in the cohorts. Results: Patients with concomitant IBD and IBS were more likely to be prescribed oral opioids (24.6% vs. 17.2% for CD; 20.2% vs. 12.3% for UC, p < 0.0001) and develop opioid dependence or abuse (p < 0.05). The subset of patients who were prescribed opioids are more likely to develop gastroesophageal reflux disease, ileus, constipation, nausea, and vomiting (p < 0.05). Conclusions: IBS is an independent risk factor for IBD patients to receive opioids and develop opioid addiction.
- 30 May 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (6) , 917
Open AccessIrritable Bowel Syndrome Is an Independent Risk Factor for Developing Opioid Use Disorder in Patients with Inflammatory Bowel Disease
Background: Symptoms of IBS can fluctuate even when IBD is in clinical remission. Patients with IBD are at an increased risk of developing opioid addiction. The aim of the study was to determine whether IBS is an independent risk factor for developing opioid addiction and related gastrointestinal symptoms in patients with IBD. Methods: We identified patients with Crohn’s disease (CD)+IBS and ulcerative colitis (UC) + IBS using TriNetX. The control groups consisted of patients with CD or UC alone without IBS. The main outcome was to compare the risks of receiving oral opioids and developing opioid addiction. A subgroup analysis was performed by selecting patients who were prescribed oral opioids and to compare with those not prescribed opioids. Gastrointestinal symptoms and mortality rates were compared in the cohorts. Results: Patients with concomitant IBD and IBS were more likely to be prescribed oral opioids (24.6% vs. 17.2% for CD; 20.2% vs. 12.3% for UC, p < 0.0001) and develop opioid dependence or abuse (p < 0.05). The subset of patients who were prescribed opioids are more likely to develop gastroesophageal reflux disease, ileus, constipation, nausea, and vomiting (p < 0.05). Conclusions: IBS is an independent risk factor for IBD patients to receive opioids and develop opioid addiction.
- Open Access
- 30 January 2023
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 29 (1) , 38-48
Clinical Characteristics of Patients With Ineffective Esophageal Motility by Chicago Classification Version 4.0 Compared to Chicago Classification Version 3.0
Michael Kurin, Syed A Adil, Sofi Damjanovska, Samuel Tanner, and Katarina Greer. J Neurogastroenterol Motil 2023;29:38-48. https://doi.org/10.5056/jnm21250
- 30 January 2023
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 29 (1) , 38-48
Open AccessClinical Characteristics of Patients With Ineffective Esophageal Motility by Chicago Classification Version 4.0 Compared to Chicago Classification Version 3.0
Michael Kurin, Syed A Adil, Sofi Damjanovska, Samuel Tanner, and Katarina Greer. J Neurogastroenterol Motil 2023;29:38-48. https://doi.org/10.5056/jnm21250
- 10 October 2022
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 57 (8) , 789-797
Trends in Gastroparesis Management
Background: There is little consensus on the medical management of gastroparesis, a disorder characterized by delayed gastric emptying with symptoms of early satiety, nausea, vomiting, and upper abdominal pain. Goals: We utilized population-level data to: (1) describe the prevalence of different pharmacological and nonpharmacological therapies in patients with gastroparesis; and (2) trend the prevalence of these therapies from 2010 to 2020. Study: More than 59 million unique medical records across 26 US-based major health care systems were surveyed using the Explorys platform to identify a cohort of adults with gastroparesis who completed both a gastric emptying study and upper endoscopy or upper gastrointestinal tract imaging. Prevalence of antiemetic, prokinetic, neuromodulator prescriptions, and surgical therapies for gastroparesis were searched within this cohort and trended annually from 2010 to 2020. Results: Antiemetics (72% of patients), prokinetics (47%), and neuromodulators (75% of patients, 44% of patients without a concomitant psychiatric or diabetic peripheral neuropathy diagnosis) were all commonly used in the treatment of patients with gastroparesis. From 2010 to 2020, there was an increase in the prevalence of antiemetic and neuromodulator prescriptions (36.4% to 57.6%, PPP=0.52). Procedural and surgical treatments were used in 5% of gastroparesis patients. Conclusions: Treatments for gastroparesis have changed over the last decade: antiemetic and neuromodulator use has increased whereas prokinetic use has remained constant. This practice pattern may reflect the growing number and availability of antiemetics and neuromodulators and the small number and known side effects of prokinetics.
- 10 October 2022
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 57 (8) , 789-797
Trends in Gastroparesis Management
Background: There is little consensus on the medical management of gastroparesis, a disorder characterized by delayed gastric emptying with symptoms of early satiety, nausea, vomiting, and upper abdominal pain. Goals: We utilized population-level data to: (1) describe the prevalence of different pharmacological and nonpharmacological therapies in patients with gastroparesis; and (2) trend the prevalence of these therapies from 2010 to 2020. Study: More than 59 million unique medical records across 26 US-based major health care systems were surveyed using the Explorys platform to identify a cohort of adults with gastroparesis who completed both a gastric emptying study and upper endoscopy or upper gastrointestinal tract imaging. Prevalence of antiemetic, prokinetic, neuromodulator prescriptions, and surgical therapies for gastroparesis were searched within this cohort and trended annually from 2010 to 2020. Results: Antiemetics (72% of patients), prokinetics (47%), and neuromodulators (75% of patients, 44% of patients without a concomitant psychiatric or diabetic peripheral neuropathy diagnosis) were all commonly used in the treatment of patients with gastroparesis. From 2010 to 2020, there was an increase in the prevalence of antiemetic and neuromodulator prescriptions (36.4% to 57.6%, PPP=0.52). Procedural and surgical treatments were used in 5% of gastroparesis patients. Conclusions: Treatments for gastroparesis have changed over the last decade: antiemetic and neuromodulator use has increased whereas prokinetic use has remained constant. This practice pattern may reflect the growing number and availability of antiemetics and neuromodulators and the small number and known side effects of prokinetics.
- 17 September 2021
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 34 (5) , e14265
Irritable bowel syndrome is strongly associated with the primary and idiopathic mast cell disorders
Background: Mounting evidence supports a mechanistic association between irritable bowel syndrome (IBS) symptoms and mast cell hyperactivity. Yet, association between IBS and mast cell disorders (MCDs) has not been studied. We examined this association using two large databases and verified with manual chart review.Methods: The IBM Watson Health Explorys database (Somers, NY), an aggregate of electronic health record (EHR) data from over two dozen US healthcare systems, and Epic's SlicerDicer tool, a self‐service tool containing de‐identified data from the Epic EHR, were used to identify patients with IBS and MCDs. Patients with organic gastrointestinal disease or diseases associated with secondary mast cell hyperproliferation were excluded. Results were verified with manual chart review from two academic centers.Key Results: Up to 4% of IBS patients had a comorbid MCD. IBS was strongly associated with all MCDs. The strongest association was between IBS and mast cell activation syndrome (OR 16.3; 95% CI 13.1–20.3). Odds ratios for IBS+urticaria, IBS+idiopathic urticaria, IBS+non‐malignant mastocytosis, and IBS+mast cell malignancy ranged from 4.5 to 9.9. Patients from each of these overlap cohorts were predominantly female, and the overlap occurred with all IBS subtypes. Thorough endoscopic evaluation and comorbid mood disorders and migraines are more common in the overlap cohorts than in IBS alone.Conclusions/Inferences: In a large US database encompassing >53 million patients over >20 years, patients with IBS are at least 4 times more likely to have a MCD than the general population. Further study of mast cell involvement in the pathogenesis of IBS is warranted.
- 17 September 2021
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 34 (5) , e14265
Irritable bowel syndrome is strongly associated with the primary and idiopathic mast cell disorders
Background: Mounting evidence supports a mechanistic association between irritable bowel syndrome (IBS) symptoms and mast cell hyperactivity. Yet, association between IBS and mast cell disorders (MCDs) has not been studied. We examined this association using two large databases and verified with manual chart review.Methods: The IBM Watson Health Explorys database (Somers, NY), an aggregate of electronic health record (EHR) data from over two dozen US healthcare systems, and Epic's SlicerDicer tool, a self‐service tool containing de‐identified data from the Epic EHR, were used to identify patients with IBS and MCDs. Patients with organic gastrointestinal disease or diseases associated with secondary mast cell hyperproliferation were excluded. Results were verified with manual chart review from two academic centers.Key Results: Up to 4% of IBS patients had a comorbid MCD. IBS was strongly associated with all MCDs. The strongest association was between IBS and mast cell activation syndrome (OR 16.3; 95% CI 13.1–20.3). Odds ratios for IBS+urticaria, IBS+idiopathic urticaria, IBS+non‐malignant mastocytosis, and IBS+mast cell malignancy ranged from 4.5 to 9.9. Patients from each of these overlap cohorts were predominantly female, and the overlap occurred with all IBS subtypes. Thorough endoscopic evaluation and comorbid mood disorders and migraines are more common in the overlap cohorts than in IBS alone.Conclusions/Inferences: In a large US database encompassing >53 million patients over >20 years, patients with IBS are at least 4 times more likely to have a MCD than the general population. Further study of mast cell involvement in the pathogenesis of IBS is warranted.
- Open Access
- 1 June 2021
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 8 (6) , e00615
Penetrating Toothpick in the Portal Vein Resulting in Refractory Multifocal Liver Abscesses
- 1 June 2021
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 8 (6) , e00615
Open AccessPenetrating Toothpick in the Portal Vein Resulting in Refractory Multifocal Liver Abscesses
- 25 January 2021
- Published by Wiley in Journal of Healthcare Risk Management
- Vol. 41 (2) , 31-39
The living will: Patients should be informed of the risks
Living wills are designed to ensure that patients’ preferences will be respected at the end of life should they lose capacity to make decisions. However, data on living will use suggest there are barriers to achieving this objective. Moreover, there is evidence that completion of a living will creates a risk of an unwanted outcome: the potential for premature withdrawal of interventions. We suggest a multifaceted approach to improve the ability of living wills to achieve their goals. However, acknowledgment of the current reality should oblige providers offering a living will to their patients to present a balanced view of living wills that includes enumeration of the risk, barriers to achieving the purported benefits, and alternatives to completing a living will, in addition to discussion of the potential benefits. This requires a change in current practice that would encourage shared decision making regarding whether completing a living will or other type of advance directive is desired by the patient and discourage the proliferation of living wills completed without providing these important advantages and disadvantages to the patient.
- 25 January 2021
- Published by Wiley in Journal of Healthcare Risk Management
- Vol. 41 (2) , 31-39
The living will: Patients should be informed of the risks
Living wills are designed to ensure that patients’ preferences will be respected at the end of life should they lose capacity to make decisions. However, data on living will use suggest there are barriers to achieving this objective. Moreover, there is evidence that completion of a living will creates a risk of an unwanted outcome: the potential for premature withdrawal of interventions. We suggest a multifaceted approach to improve the ability of living wills to achieve their goals. However, acknowledgment of the current reality should oblige providers offering a living will to their patients to present a balanced view of living wills that includes enumeration of the risk, barriers to achieving the purported benefits, and alternatives to completing a living will, in addition to discussion of the potential benefits. This requires a change in current practice that would encourage shared decision making regarding whether completing a living will or other type of advance directive is desired by the patient and discourage the proliferation of living wills completed without providing these important advantages and disadvantages to the patient.